22-Sep-2016 - Colorcon and Dow have expanded a nine year controlled release alliance to include further solubility, coating and ion exchange platforms.
19-Sep-2016 - Shire says it will appeal a decision invalidating a patent surrounding the controlled-release composition of its ulcerative colitis drug Lialda (mesalazine).
14-Sep-2016 - Lonza has licensed rights to synthetic adeno-associated viral (AAV) vectors developed by scientists at US hearing research centre, Massachusetts Eye and Ear.
14-Sep-2016 - AstraZeneca has struck a supply deal with Bespak for components in pressurised metered-dose inhalers (pMDIs) for a recently approved COPD treatment.
14-Sep-2016 - Aptar Pharma has formed an alliance with Becton, Dickinson & Co to develop new self-injection devices that will tap into the strong growth in injectable drugs.
13-Sep-2016 - Novo Nordisk has recalled six lots of its GlucaGen HypoKit pen in the US after customers in Europe complained of detached needles.
13-Sep-2016 - Catalent has announced its intention to buy Pharmatek Laboratories to boost its drug bioavailability offering.
12-Sep-2016 - Spanish API maker Suanfarma has acquired a stake in contract manufacturer and spray-drying specialist Idifarma, boosting its international presence.
12-Sep-2016 - Gerresheimer has agreed to sell its lab glassware business to a private equity investor, describing the deal as part of an effort to focus on delivery devices and pharmaceutical packaging.
07-Sep-2016 - Allergan has added to its fast-growing eye health portfolio by buying gene therapy firm RetroSense Therapeutics for $60m (€53m) upfront.
05-Sep-2016 - Aluminium adjuvants should not be used in trial placebos according to UK scientists who say the differing physical and biological properties of alum salt forms makes some safer than others.
01-Sep-2016 - PharmaJet has inked a multi-year deal with the World Health Organization for its needle-free technology, which uses 80% less vaccine than traditional methods.
01-Sep-2016 - Recipharma will provide pellet coating technology for controlled release drugs to Tillotts Pharma as part of a long-term manufacturing deal.
31-Aug-2016 - For drug molecules, having a flexible rather than a rigid structure can sometimes make you a better medicine, say scientists in California.
30-Aug-2016 - A device that isolates and sprays a patient’s own stem cells onto serious burns could have significant implications in the organ regeneration industry, says developer RenovaCare.
30-Aug-2016 - Catalent has more than doubled its biologics business since it went public in 2014, but the sector still represents less than 5% of the CDMO’s revenues.
25-Aug-2016 - Grunenthal has reiterated the benefits of its anti-crush intac tech after licensee Endo withdrew its request to have Opana ER labelled as “abuse deterrent."
17-Aug-2016 - Biomanufacturing demand will drive revenues for Patheon according to an Evercore ISI analyst, who has predicted the newly-listed CDMO will strengthen its capabilities through M&A.
16-Aug-2016 - Drug manufacturers that change hard gelatin capsule suppliers do not need to seek approval beforehand under a policy introduced by the US FDA this week.
16-Aug-2016 - Phages, peptides and live biotherapeutics could help combat antibiotic-resistant bacteria but don’t expect heavy R&D investment until people start dying from post-operative infection, says EpiBiome.
08-Aug-2016 - Alnylam’s RNAi manufacturing plant will be operational by 2018 and the firm says it is willing to invest in a second facility depending on its pipeline success.
02-Aug-2016 - Acino has agreed to sell its transdermal delivery patch business Luye Pharma Group in a deal that will include its manufacturing site in Miesbach, Germany.
01-Aug-2016 - Regulatory approvals are driving interest in West's Smartdose and Crystal Zenith delivery technologies, the firm says ahead of the launch of a monthly-dose version of Amgen's Repatha.
01-Aug-2016 - The MHRA has granted Oxford Biomedica permission to develop and manufacture cell therapies at two more sites in the UK.
25-Jul-2016 - Subcutaneous versions of its biologic blockbusters - including Mabthera and Herceptin - will help protect against biosimilar competition, says Roche.